Worth reading
51Recurring
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Who is moving to which position
Resolved 27 March 2026Incoming appointee
2 itemsScheduled Appointment DateDirectors and Audit & Supervisory Board members: late June 2026 (subject to approval at the 106th Annual General Meeting of Shareholders scheduled for June 2026) / Executive officer: effective 1 July 2026
Enomoto Masahiko (榎本 政彦)
Previous positionTax accountant / Enomoto Masahiko Tax Accountant Office
New positionOutside Corporate Auditor
Nakazawa Makoto (中澤 信)
Previous positionGeneral Manager of Pharmaceutical Sales Department
New positionExecutive Officer, Deputy General Manager of Sales Headquarters and General Manager of Pharmaceutical Sales Department
Departing officer
1 itemDate of departureLate June 2026
Matsumoto Hiroaki (松本 洋明)Next role stated
Former PositionOutside Corporate Auditor
New positionRetirement
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
Will not remain on the board (retiring as an Audit & Supervisory Board member)
Directors after the change8Number
Shareholders’ meeting approvalYes. Proposal: Appointment of directors and Audit & Supervisory Board members (106th Annual General Meeting of Shareholders scheduled for June 2026)
| Item | Details |
|---|---|
| Resolution date | 27 March 2026 |
| Scheduled Appointment Date | Directors and Audit & Supervisory Board members: late June 2026 (subject to approval at the 106th Annual General Meeting of Shareholders scheduled for June 2026) / Executive officer: effective 1 July 2026 |
| Date of departure | Late June 2026 |
| Name of appointee | Enomoto Masahiko (榎本 政彦), Nakazawa Makoto (中澤 信) |
| Appointee's new position | Outside Corporate Auditor, Executive Officer, Deputy General Manager of Sales Headquarters and General Manager of Pharmaceutical Sales Department |
| Appointee's previous position | Tax accountant / Enomoto Masahiko Tax Accountant Office, General Manager of Pharmaceutical Sales Department |
| Name of departing officer | Matsumoto Hiroaki (松本 洋明) |
| Former position of departing officer | Outside Corporate Auditor |
| New position of departing officer | Retirement |
| Whether the incumbent will remain in office | Will not remain on the board (retiring as an Audit & Supervisory Board member) |
| Number of directors after the change | 8 directors (including 3 outside directors) |
| Subject to Approval by the General Meeting of Shareholders | Yes. Proposal: Appointment of directors and Audit & Supervisory Board members (106th Annual General Meeting of Shareholders scheduled for June 2026) |
Items this document does not state (9)
Appointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureReason for changeReasons for appointmentFiling as an independent officerDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No reason for the changes is provided.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.